Cambrex completes expansion and manufacturing capability upgrades in Milan

18 Mar 2019

New laboratory has installed a flow chemistry system to allow for continuous manufacturing development.

Cambrex has completed the expansion of a new 150 m2 research and development laboratory at its site in Paullo, Milan, Italy. In addition, Cambrex has installed a new 12,000-L reactor into one of its cGMP manufacturing facilities at the site.

Cambrex completes expansion and manufacturing capability upgrades in Milan

The R&D laboratory includes both chemistry and analytical development capabilities, with the installation of semi-automated glass-lined reactors, as well as analytical instruments including multiple high and ultra-performance liquid chromatography, and gas chromatography systems, which have now been qualified and validated. To complement investments at other Cambrex sites, the new laboratory has also installed a flow chemistry system to allow for continuous manufacturing development.

The installation of the 12,000-L reactor, along with the replacement of centrifuges with new, more efficient equipment in one of the site’s seven production departments, was part of a $3 million investment to upgrade and improve the efficiency of the plant which manufactures intermediates and generic APIs under GMP conditions.

“This investment is part of our ongoing strategy to ensure that the site can adapt to the growing and evolving needs of the generic API industry,” commented Aldo Magnini, Managing Director, Cambrex Milan. “Investing in key technologies such as continuous flow will allow us to look at new opportunities for the site to expand our portfolio of generic products, in a similar manner to the investment in highly potent API containment that we undertook in 2017, which allowed us to increase the number of new highly-potent oncology products in development.”

Read More

Related news

Thermo Fisher Scientific signs agreement with Lilly Oncology for companion diagnostic

Thermo Fisher Scientific signs agreement with Lilly Oncology for companion diagnostic

10 Sep 2019

Strategic agreement utilizes FDA-approved next-generation sequencing Oncomine Dx Target Test to identify RET-altered NSCLC and thyroid cancer patients who may be suitable for Lilly's RET inhibitor.

Read more 
FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development

FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development

10 Sep 2019

Delivers enhanced galactosylation for improved protein quality, and antibody binding and function.

Read more 
Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

9 Sep 2019

Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.

Read more 
Catalent to open new clinical supply facility in San Diego

Catalent to open new clinical supply facility in San Diego

6 Sep 2019

Will enhance speed to clinic through expanded early-phase clinical supply and oral dose development services.

Read more 
Take part in pharma’s largest reputation survey

Take part in pharma’s largest reputation survey

6 Sep 2019

Use your voice to shape CPhI Worldwide's third annual global survey of the major trends, changes and developments in the industry.

Read more 
BioCity backs world's first Rx to OTC switch incubator

BioCity backs world's first Rx to OTC switch incubator

5 Sep 2019

Maxwellia considered to have the skills and the expertise to deliver and reach their goal of creating the big OTC brands of the future.

Read more 
Velesco Pharma to triple its clinical manufacturing capacity

Velesco Pharma to triple its clinical manufacturing capacity

4 Sep 2019

Company's new building in Wixom, MI replace and consolidate its existing manufacturing site in Kalamazoo, MI.

Read more 
Taiwan's biggest CDMO secures FDA approval

Taiwan's biggest CDMO secures FDA approval

3 Sep 2019

Customers claim Bora's oral solid dosage Zhunan facility is in the top 5 external manufacturing facilities they’ve ever visited in the world.

Read more 
China relaxes import regulations to improve access and availability of affordable medicines

China relaxes import regulations to improve access and availability of affordable medicines

3 Sep 2019

The potential for generics to support the healthcare needs of China is significant.

Read more 
Dutch company receives €20 million for skin cancer diagnostic test

Dutch company receives €20 million for skin cancer diagnostic test

3 Sep 2019

The test can accurately predict the risk of having metastases present in the lymph nodes without having to undergo surgery to remove lymph nodes.

Read more